Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%
Market cap
$2.2B
P/E
12.2×
Fwd P/E
9.4×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

8.53 13.61 11.12 11.63
P/S ratio
1.92 2.48 1.80 2.20
P/FCF ratio
6.17 6.99 5.37 6.70
P/Operating CF
14.59 17.05 58.34 22.82
P/B ratio
1.90 2.47 1.78 2.11
EV/Sales
1.31 1.77 1.27 1.66
EV/EBITDA
4.36 6.61 5.31 6.25
EV/FCF
4.21 5.00 3.77 5.07
Current Ratio
3.75 3.60 3.58 3.48
Net Debt/EBITDA
(7.07) (13.34) (11.16) (5.41)
Debt/Equity
0.20 0.19 0.17 0.15
Earnings Yield
11.72% 7.35% 9.00% 8.60%
Free Cash Flow Yield
16.20% 14.31% 18.63% 14.92%
Free Cash Flow per Share
1.89 2.19 0.48 1.60
Book value per Share
14.51 15.14 15.74 17.25
Free Cash Flow
108.66 126.04 27.76 92.43
EV/EBIT
4.80 7.39 6.00 6.92
Other line items

Show all line items

Columns are period end dates